Bridging traditions and evidence: Qiliqiangxin in the evolving landscape of heart failure therapy
Author:
Open Access
- 1 January 2026
- journal article
- editorial
- Published by Wolters Kluwer Health in Cardiology Plus
- Vol. 11 (1) , 5-6
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Efficacy and safety of Qiliqiangxin capsule for heart failure with reduced ejection fraction: a systematic review and meta-analysisCardiology Plus, 2026
- The traditional Chinese medicine Qiliqiangxin in heart failure with reduced ejection fraction: a randomized, double-blind, placebo-controlled trialNature Medicine, 2024
- Real-world effectiveness of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a retrospective, non-interventional cohort analysisCardiology Plus, 2024
- Enhancing implementation of evidence-based heart failure therapies in clinical practice: vital to modern medicineCardiology Plus, 2024
- Qiliqiangxin: A Multifaceted Holistic Treatment for Heart Failure or a Pharmacological Probe for the Identification of Cardioprotective Mechanisms?European Journal of Heart Failure, 2023
- Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy HypothesisCirculation, 2022
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019